Premium
Hypothyroidism and goiter in a patient during treatment with interleukin‐2
Author(s) -
Mattijssen Vera J. M.,
De Mulder Pieter H. M.,
Van Liessum Peter A.,
Corstens Frans H. M.,
Franks Christopher R.,
Theo Wagener D. J.
Publication year - 1990
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19900615)65:12<2686::aid-cncr2820651215>3.0.co;2-d
Subject(s) - medicine , goiter , autoimmune thyroiditis , thyroiditis , dacarbazine , thyroid , endocrinology , chemotherapy
The development of transient hypothyroidism and goiter in a patient with a metastasized malignant melanoma during treatment with recombinant interleukin‐2 (rIL‐2) and dacarbazine is reported. Signs of autoimmune thyroiditis became apparent 2 weeks after the start of treatment and disappeared after treatment stopped. It is likely that rIL‐2 was responsible by interfering with preexisting autoimmune thyroid disease. The possible mechanisms are discussed here. Patients with positive antithyroid microsomal antibody titers are prime candidates for rIL‐2‐induced thyroiditis.